Race on to dominate head and neck cancer market; Report
US pharma majors Bristol-Myers Squibb (NYSE: BMY) and Merck & Co (NYSE: MRK) are set to continue their strong rivalry in the head and neck cancer space, as their respective PD-1 inhibitory monoclonal antibodies, Opdivo (nivolumab) and Keytruda (pembrolizumab), race to enter the market,
According to an analyst with research and consulting firm GlobalData, both drugs have shown promise in clinical trials, and are therefore set to make waves across the head and neck cancer market which, as stated in GlobalData’s most recent Head and Neck Cancer report, will grow rapidly to more than $1.5 billion by 2024.
Amy Yip, GlobalData's analyst covering oncology and hematology, says: “Recent trials evaluating Opdivo’s efficacy in recurrent or metastatic head and neck squamous cell carcinoma, found that it resulted in a 30% reduction in the risk of death, and a significant improvement compared to the only targeted agent currently approved for the disease, Eli Lilly’s Erbitux (cetuximab).”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze